• Keryx Biopharmaceuticals Inc., of New York, presented updated efficacy and safety data from the Phase III long-term trial of Zerenex (ferric citrate), the company's ferric iron-based phosphate binder drug candidate for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.